Login
News
17.09.2019 GBG Forschung beim ESMO 2019
Daten einiger GBG Forschungsprojekte werden beim ESMO 2019 vom 27. September bis 1. Oktober in Barcelona vorgestellt.
Mehr ...12.09.2019 August 2019: Results of a pooled analysis from two randomized phase III trials [LEA GBG51 and Cancer and Leukemia Group (CALGB) 40503] evaluating the addition of bevacizumab to endocrine therapy (ET) as first-line treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC)
Data from two similar randomized phase III trials (LEA GBG51 and CALGB 40503) comparing the efficacy of standard ET versus experimental ET plus bevacizumab as first-line treatment for HR-positive MBC have been published in the European Journal of Cancer
Mehr ...31.07.2019 July 2019: Fatal events occurring during study treatment: a pooled analysis of death cases within GBG led breast cancer trials
We are glad to inform you that the results of a pooled analysis evaluating fatal events during GBG led breast cancer trials have been published in the Breast Cancer
Mehr ...08.07.2019 Fortbildung Checkpoint-Inihibitoren
Fortbildungsveranstaltung „Behandlung mit Checkpoint-Inihibitoren“ der GBG und des BreastNet Rhein Main am 27. August 2019 von 17:00 – 20:00 Uhr in Frankfurt
Mehr ...